Mental Health Key Component of President Obama's Gun Control Executive Orders
Client Alert | 1 min read | 01.22.13
On January 16, 2013, President Barack Obama issued the Gun Violence Reduction Executive Actions. Of the 23 Executive Actions, 3 in particular are particularly notable to the healthcare industry:
- No. 20 is an order to "Release a letter to state health officials clarifying the scope of mental health services that Medicaid plans must cover."
- No. 21 is an order to "Finalize regulations clarifying essential health benefits and parity requirements within ACA exchanges."
- No. 22 is an order to "commit to finalizing mental health parity regulations."
The orders can be read via the Washington Post.
President Obama also released a memo to the HHS Secretary, instructing the HHS to conduct research on the cause and possible solutions to gun violence, with a focus on the research issues with an impact on public health. Specifically, the memorandum directs HHS to begin by "identifying the most pressing research questions with the greatest potential public health impact, and by assessing existing public health interventions being implemented across the Nation to prevent gun violence." Click to read the memorandum as published in the Federal Register.
Insights
Client Alert | 4 min read | 09.16.26
CMS Offers Guidance as Scrutiny Rises Over ABA Therapy in Medicaid
Between 2021 and 2025, Medicaid spending on ABA therapy grew six times faster than the number of children who received services, making it one of the fastest-growing areas of Medicaid expenditure, according to CMS. On August 4, 2026, CMS released a toolkit to help state Medicaid and CHIP agencies strengthen their programs and limit fraud, waste, and abuse tied to increased demand for ABA therapy. In 2025, Medicaid spent about $10 billion on ABA and related therapy services for children with ASD — a dramatic increase from the $2 billion spent in 2021.
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
